智通财经APP获悉，9月7日至9日，优趣汇(02177)旗下加拿大保健食品Vanpearl携手"大分子实验室"开启 新加坡溯源专场再传捷报，实现总销售额突破400万元，销售数量超过8000瓶(1)，并在7日首发场持续 霸榜抖音保健食品带货榜TOP1，直播间流量与转化表现超高(2)。 备注： Vanpearl作为优趣汇重点孵化的加拿大保健食品品牌，其核心产品ERGO - VITALIS™基因胶囊，凝聚了 前沿科研智慧与创新成分，产品蕴含着修复DNA延缓衰老的专利配方，它能精准激活细胞本源的生命 因子，有效替换受损DNA基因片段，同时全方位保护DNA基因组稳定，从根本上提升细胞自我修复效 率与代谢效率，实现细胞DNA基因层面的抗衰老效果，堪称 "基因守护者"。 此次Vanpearl与大分子合作的新加坡溯源专场，不仅实现了流量与转化的双高表现，也进一步巩固了其 在高端保健品市场的品牌影响力。优趣汇也凭借着在供应链、品牌运营与跨境电商领域的整合能力，持 续推动自有品牌与国际科研资源对接。 (1)以上销售及数量数据取自9月7号-9月9号，数据来源于飞瓜 (2)9月7号基因胶囊新加坡研学专场首发8点-9点持续霸榜保健食品 ...

Core Viewpoint - The financial results of Youquhui (02177) for the first half of 2025 show a revenue of 580 million yuan and a net profit of 11.2 million yuan, indicating a "zero growth" situation. However, excluding non-recurring items and terminated brand collaborations, revenue increased by 2.5% year-on-year, and net profit remained stable. The gross margin improved by 4.6 percentage points to 34.6% [1] Group 1: "Subtraction" Strategy - Youquhui has been actively divesting low-margin brands and channels, which has led to a continuous improvement in profitability. The gross margin has shown a significant upward trend, increasing from 23.9% in 2022 to 34.6% in the first half of 2025 [2] - The company terminated collaborations with low-margin brands in the personal care and beauty sectors, as well as ceased operations in stagnant e-commerce businesses, indicating a strategic shift towards higher-margin products [2] - The rising gross margin trend is a key indicator of potential future improvements in other performance metrics, despite short-term fluctuations in revenue and net profit [2] Group 2: "Addition" Strategy in Health Sector - Youquhui has identified the health sector as a primary area for diversification, capitalizing on the growing demand for functional health foods. The health segment's revenue grew by 42.9% in the first half of 2025, driven by the strong performance of its proprietary brand Vanpearl, which generated 14 million yuan in revenue [3][4] - The successful launch of the ERGO-VITALIS™ capsule, which utilizes ergothioneine as a key ingredient, has validated the company's health product development model [3] - Youquhui is expanding its partnerships with established health brands, enhancing its market presence and brand influence in the health sector [3] Group 3: Future Growth Potential - The company's mid-year report reflects a strategic investment phase, with a clear long-term growth trajectory despite the absence of immediate steep growth in core financial metrics [5] - Youquhui plans to prioritize overseas expansion, particularly in Southeast Asia and North America, utilizing localized compliance and collaboration with local KOLs to enhance brand visibility and market penetration [6] - The company has shifted its funding strategy from seeking investments in technology companies to focusing on acquisitions and strategic partnerships in the health and beauty sectors, indicating a proactive approach to seizing growth opportunities [6]

Core Insights - The company reported a revenue of approximately 580 million and a net profit of 11.2 million for the first half of 2025, with basic earnings per share at 0.07 yuan [1] - The company has systematically optimized its brand matrix, terminating partnerships with low-margin brands, resulting in a 2.5% revenue increase compared to the same period last year [1] - The gross margin for the first half of 2025 was 34.6%, an increase of 4.6 percentage points from 30.0% in the same period last year [1] Revenue and Profitability - The company actively optimized its existing brand and channel structure, focusing on enhancing cooperation with core brand partners and expanding overseas markets [1] - New health brands were introduced, contributing an additional revenue of 12.5 million [1] - Revenue from Douyin, Pinduoduo, and overseas businesses accounted for 12.4% of total revenue, up from 11.1% in the same period last year, marking an increase of 1.3 percentage points [1] Product Development - The company launched a Canadian anti-aging health food brand, Vanpearl, featuring the active ingredient ergothioneine, generating sales revenue of 14 million [2] - A strategic partnership was established with Novo Nordisk's high-end probiotic brand, focusing on high-net-worth consumers in China who prioritize gut health [2] - The company is strengthening its competitive advantage in the high-end health food sector through a diversified product portfolio [2]